Who is sponsoring NCT03742050?

NCT03742050 is sponsored by Imperial College London.

What drugs are being tested in NCT03742050?

Interventions in NCT03742050: Percutaneous coronary intervention.

What condition does NCT03742050 study?

NCT03742050 studies Stable Angina.

Is NCT03742050 still recruiting?

NCT03742050 is currently completed. Last updated 29 September 2023.

Last reviewed 2023-09-29 · How we verify

NCT03742050: ORBITA-2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Placebo-controlled Trial of Percutaneous Coronary Intervention for the Relief of Stable Angina

Completed NA Last updated 29 September 2023

What this trial tests

NA trial testing Percutaneous coronary intervention in Stable Angina in 439 participants. Completed in 6 September 2023.

Timeline

12 November 2018

Primary endpoint
6 September 2023

6 September 2023

Quick facts

Lead sponsor	Imperial College London
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	439
Start date	12 November 2018
Primary completion	6 September 2023
Estimated completion	6 September 2023
Sites	8 locations across United Kingdom

Drugs / interventions tested

Percutaneous coronary intervention

Conditions studied

Stable Angina — all drugs for Stable Angina →

Sponsor

Imperial College London

Who can join

Adults 18 to 85, any sex, with Stable Angina. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

ORBITA-2 is a double blinded randomised placebo-controlled trial comparing the effects of coronary angioplasty versus placebo procedure on symptoms of stable angina without background anti-anginal therapy. Follow-up will be at 12 weeks.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina.
Rajkumar CA, Foley MJ, Ahmed-Jushuf F, Nowbar AN, et al · · 2023 · cited 147× · PMID 38015442 · DOI 10.1056/nejmoa2310610
Cardiopulmonary exercise testing and efficacy of percutaneous coronary intervention: a substudy of the ORBITA trial.
Ganesananthan S, Rajkumar CA, Foley M, Thompson D, et al · · 2022 · cited 21× · PMID 35639660 · DOI 10.1093/eurheartj/ehac260
Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Coronary Artery Disease.
Foley MJ, Rajkumar CA, Ahmed-Jushuf F, Simader F, et al · · 2025 · cited 17× · PMID 39462291 · DOI 10.1161/circulationaha.124.072281
Remote digital smart device follow-up in prospective clinical trials: early insights from ORBITA-2, ORBITA-COSMIC, and ORBITA-STAR.
Ganesananthan S, Rajkumar CA, Foley M, Francis D, et al · · 2022 · cited 16× · PMID 36382002 · DOI 10.1093/eurheartjsupp/suac058
A double-blind randomised placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina without antianginal medications: design and rationale of the ORBITA-2 trial.
Nowbar AN, Rajkumar C, Foley M, Ahmed-Jushuf F, et al · · 2022 · cited 15× · PMID 35156616 · DOI 10.4244/eij-d-21-00649
Improving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review.
Marquis-Gravel G, Moliterno DJ, Francis DP, Jüni P, et al · · 2020 · cited 8× · PMID 32703515 · DOI 10.1016/j.jacc.2020.05.060
Optimising physiological endpoints of percutaneous coronary intervention.
Al-Lamee R, Rajkumar CA, Ganesananthan S, Jeremias A. · · 2021 · cited 7× · PMID 33792544 · DOI 10.4244/eij-d-20-00988
Association Between Age and PCI Effectiveness in Stable CAD: Secondary Analysis of ORBITA-2.
Simader FA, Rajkumar CA, Foley MJ, Ahmed-Jushuf F, et al · · 2026 · cited 1× · PMID 41603507 · DOI 10.1016/j.jacc.2025.10.086

Verify or expand the search:

Other trials of Percutaneous coronary intervention

Trials testing the same drug.

NCT07349979 — PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy · NA · not yet recruiting
NCT07457320 — Development and Validation of a Multimodal Artificial Intelligence Model for Early Prediction of Acute Myocardial Infarc · not yet recruiting
NCT07449052 — Comprehensive Invasive Physiological Evaluation of Obstructive Coronary Artery Disease · NA · not yet recruiting
NCT07250152 — Enhanced Prediction Model for Major Adverse Events Following Acute Myocardial Infarction · not yet recruiting
NCT06399705 — REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Minorities · Phase 3 · recruiting

Other recruiting trials for Stable Angina

Currently open trials in the same condition.

NCT06436092 — Japanese Coronary Intervention Using Drug Eluting and Perfusion Therapy for Left Main Disease (JDEPTH-LM Registry) · recruiting
NCT05972070 — Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence · recruiting
NCT05865600 — Perfusion Estimation For Optimal Treatment Strategy in Chronic Coronary Syndrome · NA · recruiting
NCT05230446 — PRospective Evaluation of Complete Revascularization in Patients With multiveSsel Disease Excluding chroNic Total Occlus · NA · recruiting
NCT05255705 — Barts Revascularisation Registry · recruiting

Other Imperial College London trials

Trials by the same sponsor.

NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03742050 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Imperial College London
Last refreshed: 29 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03742050.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing